Minocycline reduces engraftment and activation of bone marrow‐derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Bone marrow (BM)‐derived monocytes contribute to the development of microglial reaction around β‐amyloid (Aβ) plaques in Alzheimer's disease (AD) and possibly clear Aβ. Therefore, it is of great importance to separate the proinflammatory actions of monocytic cells from Aβ phagocytic effects. We used minocycline (mino) to systemically downregulate microglial activation and studied proliferation, expression of markers for activated microglia, and Aβ removal in vitro and in vivo. Mino did not affect proliferation or phagocytic activity of BM‐derived cells toward Aβ in vitro. Intrahippocampal LPS injection used to induce inflammation and increase recruitment of BM cells from periphery, reduced Aβ burden in BM‐transplanted AD transgenic mice. All engrafted cells expressed CD45, ∼50% expressed Iba‐1, and <0.5% of these cells expressed CD3e. About 40% of the engrafted cells were mitotically active. LPS increased immunoreactivity for Iba‐1, MHC II, a marker of antigen presenting cells, and CD68, a marker of lysosomal activity. The endogenous microglia largely contributed to these LPS‐induced immunoreactivities. Mino reduced the engraftment of BM‐derived cells and blocked the LPS‐induced MHC II and Iba‐1 immunoreactivities, but did not prevent the increased CD68‐immunoreactivity or the reduced Aβ burden. Importantly, mino did not block the association of eGFP‐positive cells with Aβ deposits and the percentage of mitotically active BM‐derived cells. In conclusion, mino reduces overall inflammatory potential of BM‐derived monocytic cells without preventing their phagocytic activity. The separation of harmful activation of microglia/monocytic cells from their Aβ clearing mechanism may hold important therapeutic potential. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
‘Green mice’ as a source of ubiquitous green cells
Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T., & Nishimune, Y. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00313-x · Cited by 2,581 · cited 2×
“transgene (Okabe et al., 1997) were purchased from Jackson Laboratories (Maine, USA) and were maintained in C57BL/6j strain in the Animal Facilities of the”
MethodBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08370.2001 · Cited by 1,530
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 2×
“(Henderson et al., 1997; McGeer et al., 1996; Stewart et al., 1997) has led to the hypothesis that inflammation is a driving force in AD pathogenesis (Akiyama et al.”
BackgroundRisk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 1×
“(Chen et al., 2000; Du et al., 2001; Power et al., 2003; Sanchez Mejia et al., 2001; Tikka and Koistinaho, 2001; Tikka et al., 2002; Yrjanheikki et al., 1998; Yrjanheikki et al., 1999; Zhu et al., 2002).”
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958 · cited 1×
“On the contradictory, mino prevents microglial proliferation in vitro (Tikka et al., 2001) under certain conditions, suggesting that the effect of mino on cell proliferation may depend on age (adult microglia in vivo versus neonatal microglia in vitro) and growth conditions/environmental factors.”
BackgroundAdult mouse astrocytes degrade amyloid-β in vitro and in situ
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., & Husemann, J. (2003) · Nature Medicine · doi:10.1038/nm838 · Cited by 909
Priller, J., Flügel, A., Wehner, T., Boentert, M., Haas, C. A., Prinz, M., Fernández-Klett, F., Prass, K., Bechmann, I., de Boer, B. A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1356 · Cited by 637
TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
Wyss-Coray, T., Lin, C., Yan, F., Yu, G.-Q., Rohde, M., McConlogue, L., Masliah, E., & Mucke, L. (2001) · Nature Medicine · doi:10.1038/87945 · Cited by 587
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides
Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1058 · Cited by 571 · cited 3×
“To analyze insoluble fraction of Ab, the remaining pellet was resolved in guanidine buffer (5.0 M guanidine-HCl/50 mM Tris-HCl, pH 8.0).”
MethodSelf-citationPhenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
Frautschy, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00300-1 · Cited by 514
Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases
Togo, T., Akiyama, H., Iseki, E., Kondo, H., Ikeda, K., Kato, M., Oda, T., Tsuchiya, K., & Kosaka, K. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00496-9 · Cited by 481 · cited 1×
“Earlier studies have suggested some involvement of T cells in AD brain (Itagaki et al., 1988; Stalder et al., 2005; Togo et al., 2002); however, their role in the disease pathogenesis has remained unknown.”
BackgroundKoenigsknecht-Talboo, J., & Landreth, G. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1808-05.2005 · Cited by 477 · cited 1×
“Interestingly, it has been shown that proinflammatory cytokines inhibit microglial phagocytosis of fibrillar Ab in vitro and that ibuprofen, a commonly used NSAID, markedly relieves this proinflammatory-induced suppression of phagocytosis (Koenigsknecht-Talboo and Landreth, 2005).”
BackgroundProminent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446 · cited 1×
“…and Lue, 2001), others have shown that activation of microglial/monocytic cells is beneficial as it may facilitate the clearance of Ab from the brain and participate in the regeneration of CNS after injury (Bard et al., 2000; Schenk et al., 1999; Wyss-Coray et al., 2001; Wyss-Coray et al., 2002).”
BackgroundMalm, T. M., Koistinaho, M., Pärepalo, M., Vatanen, T., Ooka, A., Karlsson, S., & Koistinaho, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.009 · Cited by 301 · cited 11×
“The modulation of microglial/macrophage inflammatory properties without affecting their phagocytic capacity may hold potential therapeutic strategies, as the blood-derived monocytic cells have increased engraftment to the brain and around Ab deposits in AD mice (Malm et al., 2005).”
BackgroundMethodResultSelf-citationItagaki, S., McGeer, P. L., & Akiyama, H. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90690-8 · Cited by 271 · cited 1×
“Earlier studies have suggested some involvement of T cells in AD brain (Itagaki et al., 1988; Stalder et al., 2005; Togo et al., 2002); however, their role in the disease pathogenesis has remained unknown.”
BackgroundRogers, J., & Lue, L.-F. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00040-7 · Cited by 236 · cited 1×
“…several studies have provided evidence that microglia/monocytic cells contribute to the neurodegeneration by releasing these destructive factors (Rogers and Lue, 2001), others have shown that activation of microglial/monocytic cells is beneficial as it may facilitate the clearance of Ab from…”
ResultRabinowitz, S. S., & Gordon, S. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.827 · Cited by 233 · cited 1×
“Mouse macrosialin CD68 is a lysosomal-associated protein that is found in the late endosomes and has been linked with the phagocytic capacity of cells (da Silva and Gordon, 1999; Rabinowitz and Gordon, 1989; Rabinowitz and Gordon, 1991).”
BackgroundWilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232 · cited 3×
“…of MHC II and CD45 has been associated with microglial/macrophage activation upon similar experimental setup in earlier reports (Di Carlo et al., 2001; Malm et al., 2005; Wilcock et al., 2003) and our cell counts revealed that 70% of the MHC II-positive cells in the brain were eGFP positive.”
BackgroundResultIntrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice
DiCarlo, G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00292-5 · Cited by 223
Wilcock, D. M., Munireddy, S. K., Rosenthal, A., Ugen, K. E., Gordon, M. N., & Morgan, D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.015 · Cited by 202
Blais, V., Turrin, N. P., & Rivest, S. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03480.x · Cited by 72
Cited by
Lipopolysaccharide-induced neuroinflammation as a bridge to understand neurodegeneration
Batista, C. R. A., Gomes, G. F., Candelario-Jalil, E., Fiebich, B. L., & de Oliveira, A. C. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092293 · Cited by 529
“Another study showed that intrahippocampal LPS injection increased by about sixfold the bone marrow cells recruitment from the periphery and reduced Aβ clearance in bone marrow-transplanted AD transgenic mice [48].”
BackgroundMethodDrug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 301
Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization
Zotova, E., Bharambe, V., Cheaveau, M., Morgan, W., Holmes, C., Harris, S., Neal, J. W., Love, S., Nicoll, J. A. R., & Boche, D. (2013) · Brain · doi:10.1093/brain/awt210 · Cited by 272
Microglia and neuroprotection: From in vitro studies to therapeutic applications
Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 262
Pey, P., Pearce, R. K., Kalaitzakis, M. E., Griffin, W. S. T., & Gentleman, S. M. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-21 · Cited by 128
Metadata
- Authors
- Malm, T. M., Magga, J., Kuh, G. F., Vatanen, T., Koistinaho, M., & Koistinaho, J.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2008-07-22
- Volume
- 56
- Issue
- 16
- Pages
- 1767-1779
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2074643069
- Cited by
- 52
- References
- 25
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.